Dataset Information
Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer.
Ontology highlight
ABSTRACT: Aim
To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies.Methods
We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.Results
All treatment schemes showed an antagonistic effect in all cell lines, independent of the cMET status. Despite their different genetic backgrounds, all cell lines (EBC-1, HCC827, H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7. These results were independent of the treatment schedule.Conclusion
These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC.
SUBMITTER: Van Der Steen N
PROVIDER: S-EPMC5143436 | biostudies-literature | 2016 Dec
REPOSITORIES: biostudies-literature
Publications
Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer.
World journal of clinical oncology 20161201 6
<h4>Aim</h4>To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed <i>in vitro</i> combination studies.<h4>Methods</h4>We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.<h4>Results</h4>All treatment schemes showed an antagonistic effect in all cell l ...[more]